The purpose of this legislation is to address unfair international trade practices by high-income countries that exploit American pharmaceutical innovations. It aims to ensure that these countries adhere to market-based policies and do not undermine the value of U.S. innovations, particularly in the pharmaceutical sector. Key provisions of the legislation include the establishment of a Chief Pharmaceutical Trade Negotiator. This official will conduct trade negotiations and enforce agreements related to U.S. pharmaceutical products.